Targeting Strategies for Tissue-Specific Drug Delivery

Zongmin Zhao; Anvay Ukidve; Jayoung Kim; Samir Mitragotri

doi:10.1016/j.cell.2020.02.001

Targeting Strategies for Tissue-Specific Drug Delivery

Cell. 2020 Apr 2;181(1):151-167. doi: 10.1016/j.cell.2020.02.001.

Authors

Zongmin Zhao¹, Anvay Ukidve¹, Jayoung Kim¹, Samir Mitragotri²

Affiliations

¹ John A. Paulson School of Engineering and Applied Sciences, Harvard University, MA 02138, USA; Wyss Institute of Biologically Inspired Engineering at Harvard University, Boston, MA 02115, USA.
² John A. Paulson School of Engineering and Applied Sciences, Harvard University, MA 02138, USA; Wyss Institute of Biologically Inspired Engineering at Harvard University, Boston, MA 02115, USA. Electronic address: mitragotri@seas.harvard.edu.

PMID: 32243788
DOI: 10.1016/j.cell.2020.02.001

Abstract

Off-target effects of systemically administered drugs have been a major hurdle in designing therapies with desired efficacy and acceptable toxicity. Developing targeting strategies to enable site-specific drug delivery holds promise in reducing off-target effects, decreasing unwanted toxicities, and thereby enhancing a drug's therapeutic efficacy. Over the past three decades, a large body of literature has focused on understanding the biological barriers that hinder tissue-specific drug delivery and strategies to overcome them. These efforts have led to several targeting strategies that modulate drug delivery in both the preclinical and clinical settings, including small molecule-, nucleic acid-, peptide-, antibody-, and cell-based strategies. Here, we discuss key advances and emerging concepts for tissue-specific drug delivery approaches and their clinical translation.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

MeSH terms

Drug Delivery Systems*
Drug Design*
Humans
Pharmaceutical Preparations / chemistry*

Substances

Pharmaceutical Preparations